Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13716857 | 0.86 | KMT2A (0.45) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL6169765 | 0.81 | KMT2A (0.49) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL29439591 | 0.79 | KMT2A (0.47) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL628538 | 0.79 | KMT2A (0.47) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL4225491 | 0.79 | KMT2A (0.69) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL13716846 | 0.79 | KMT2A (0.47) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL21617345 | 0.79 | KMT2A (0.47) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL15507979 | 0.79 | ALDH1A1 (0.42) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL17024284 | 0.79 | ALDH1A1 (0.42) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL31507703 | 0.79 | ALDH1A1 (0.42) | KMT2AMEN1L3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-19 | — | — | US | disclosed |
| EP-3293183-B1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-05-24 | — | — | US | disclosed |
| EP-3293183-A1 | INHIBITOR COMPOUNDS | Cancer Research Technology Ltd. (GB) | 2018-03-14 | — | — | EP | disclosed |
| US-9890157-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-9834552-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| EP-2892889-B1 | INHIBITOR COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9409907-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160220570-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160222009-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20150239884-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | BUB1B, BUB1, CDK1 | KMT2A 2725/4885MEN1 601/4885L3MBTL1 2470/4885 |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | KMT2A 2793/4885MEN1 457/4885L3MBTL1 2606/4885 |
| US-20150239884-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | KMT2A 2793/4885MEN1 457/4885L3MBTL1 2606/4885 |
| US-11046688-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | KMT2A 2793/4885MEN1 457/4885L3MBTL1 2606/4885 |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | KMT2A 2793/4885MEN1 457/4885L3MBTL1 2606/4885 |
| US-20160222009-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | KMT2A 2793/4885MEN1 457/4885L3MBTL1 2606/4885 |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | KMT2A 2793/4885MEN1 457/4885L3MBTL1 2606/4885 |
| US-20160220570-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | KMT2A 2793/4885MEN1 457/4885L3MBTL1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.